Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05058092
Other study ID # Remedee3/Fibrepik
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 15, 2021
Est. completion date February 28, 2023

Study information

Verified date March 2023
Source Remedee SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fibromyalgia is a chronic and complex condition with symptoms that have a strong impact of patients' quality of life, including musculoskeletal pain, insomnia, fatigue, and stiffness. These symptoms are due to a dysfunction of the central nervous system, namely increased sympathetic and decreased parasympathetic levels of activity, and a deficit in endogenous pain inhibition. Remedee Labs is developing a unique technology using millimeter waves to stimulate subcutaneous nerve receptors of the wrist, sending a message to the brain, which in turn releases endorphins. These endorphins induce a hypoalgesic effect and activate the parasympathetic nervous system, which reduces pain, stress, and improves sleep. The Remedee Solution evaluated in this study is a wristband designed to deliver millimeter wave, a mobile application that allows the patient to follow his treatment sessions and a personalized support which aims to improve patient adherence to the technology and to increase compliance and effectiveness of the treatment. The hypothesis of this study is that regular use of the Remedee Solution for three months improves the quality of life of fibromyalgia patients.


Recruitment information / eligibility

Status Completed
Enrollment 170
Est. completion date February 28, 2023
Est. primary completion date July 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - clinical diagnosis of fibromyalgia according to the American College of Rheumatology criteria (Wolfe et al., 2016), - FIQ score = 39 (moderate and higher forms) on the day of inclusion (D0), - with a smartphone that runs on Android 8 and iOS 12 or later, - agreeing the installation of the Fibrepik app on the smartphone, - agreeing the collection of the number of steps measured by the smartphone, - agreeing the installation of the Google Fit app for patients whose smartphone runs on Android (necessary for the collection of the number of steps), - wrist size compatible with the size M or L of the wristband template, - affiliated to the social security system or beneficiary of such a system, - who have signed a consent to participate. Exclusion Criteria: - with a characterized depressive episode according to the DSM 5, - substantial change in treatment in the three months prior to inclusion and in the months to come: change in analgesic level, introduction of a new treatment. - with a chronic inflammatory pathology (chronic inflammatory rheumatism, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, lupus,...), - person in civil proceedings, - having a dermatological pathology on the wrists, such as oozing dermatosis, hyper sweat or an unhealed lesion, - with a surgical implant, tattoo or piercing on one of the wrists, - allergic to metals and/or silicone, - referred to articles L1121-5 to L1121-8 of the French Public Health Code (CSP): Pregnant, parturient or nursing woman; Person deprived of liberty by judicial or administrative decision; Person subject to a legal protection measure or unable to express his/her consent; Person under psychiatric care - in a period of exclusion from other interventional research.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Immediate Remedee Solution
D0 to M3: Remedee Solution + medical care M3 to M6: Remedee Solution without personalized support + medical care M6 to M9: medical care only
Delayed Remedee Solution
D0 to M3: medical care only M3 to M6: Remedee Solution + medical care M6 to M9: Remedee Solution without personalized support + medical care

Locations

Country Name City State
France University Hospital of Grenoble Alps Grenoble
France CHU de Montpellier Montpellier
France Cabinet libéral Dr. Lorenzi-Pernot Mornant
France Hôpital Lariboisière - Assistance Publique Hôpitaux de Paris Paris
France CHU de Rouen Rouen
France Hôpital Foch Suresnes
France Centre Hospitalier de Valenciennes Valenciennes
France Médipôle hôpital mutualiste Villeurbanne

Sponsors (1)

Lead Sponsor Collaborator
Remedee SA

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients who significantly improve their fibromyalgia-specific quality of life on the FIQ questionnaire between the inclusion visit at D0 and the 3-month visit (M3). A decrease in FIQ score = 14% is considered clinically meaningful (Bennett et al., 2009) 3 months
Secondary Evolution of the quality of sleep between D0 and M3 on the Pittsburg Sleep Quality Index (PSQI) questionnaire. The score of the PSQI questionnaire is between 0 and 21. The higher score (21) means the worse quality of sleep. 3 months
Secondary Evolution between D0 and M3 of the average pain score over the week on a Visual Analogic Scale (VAS). The score of the VAS is beetween 0 and 10. The higher score (10) means the worse pain. 3 months
Secondary Evolution between D0 and M3 of anxiety and depression on the Hospital and Anxiety Depression scale (HAD). The HAD scale has two dimensions: anxiety score is between 0 and 21 and depression score is between 0 and 21. The higher score means the worse anxiety or depression.
To screen for anxiety and depressive symptoms, the following interpretation can be proposed for each of the scores:
<7 : no symptomatology
8 to 10: doubtful symptomatology
>11 : definite symptomatology.
3 months
Secondary Evolution between D0 and M3 of fatigue between the two groups on the Multidimensional Fatigue Inventory questionnaire (MFI20) The MFI is a 20-item scale designed to evaluate five dimensions of fatigue: general fatigue, physical fatigue, reduced motivation, reduced activity, and mental fatigue.
The score of each dimension is between 4 and 20. Higher score correspond with more acute levels of fatigue.
3 months
Secondary Evolution of analgesic, antidepressant and sleeping pill intake between D0 and M3 Patient-reported class, dose and number of analgesic doses, as well as dose and number of antidepressant and sleep medication doses. Both self-prescription and heteroprescription will be counted. 3 months
Secondary Consumption of care between D0 and M3 number of:
care (procedures, medical consultations, hospitalizations),
complementary care (acupuncture, osteopath, naturopath, etc.),
psycho-behavioral therapies,
complementary treatments (phytotherapy, homeopathy, food supplements).
3 months
Secondary Evolution between D0 and M3 of the general quality of life on the EQ-5D-5L questionnaire The EQ-5D-5L is a standardized instrument developped by the Euroquol Group as a measure of health-related quality of life. The EQ-5D-5L contains 5 questions (5Q) with response rated in 5 level (5L) and a visual-analogue-scale between 0 and 100. Responses of the 5 questions results to index. 3 months
Secondary Evolution between D0 and M3 of physical activity on the Global Physical Activity Questionnaire (GPAC). Each object has a specific code starting from P1 to P16 and then activity is calculated in MET value. For Work and Recreational domains, Moderate MET value is 4.0 and Vigorous MET value is 8.0 while for Transport domains MET value is 4.0 3 months
Secondary Evolution of number of steps measured by the subject's smartphone collected from D0 to M3 through the Fibrepik mobile application. 3 months
Secondary Impression of the disease change by the patient on the Patient Global Impression of Change (PGIC) at M3 The PGIC scale is a 7 point scale depicting a patient's rating of overall improvement. 3 months
Secondary Impression of the disease change by the caregiver on the Clinician Global Impression of Change (CGIC) scale at M3 The CGIC scale is a 7 point scale depicting a patient's rating of overall improvement. 3 months
Secondary Frequency of use of the wristband on the six months of use it Analyses of log file of wristband month 6 for Intervention groupe and month 9 for control group
Secondary Usability of the wristband on the modular evaluation of key Components of User Experience (meCUE) questionnaire. The questionnaire includes 30 items divided into four independent modules: product perception, emotions, consequence of use and global evaluation.
For modules 1 to 3, the user indicates his or her level of agreement with statements on a 7-point Likert scale, from "strongly disagree" to "strongly agree.
The last question of the meCUE (module 4) asks the user to give an overall evaluation of the product on a scale from - 5 (bad) to + 5 (good).
month 6 for Intervention groupe and month 9 for control group
Secondary Remedee Solution satisfaction questionnaire (questionnaire created by the sponsor) This questionnaire specific to the Remedee Solution includes three parts in order to evaluate the patient's satisfaction with the bracelet, the mobile application and the support. A global score between 0 and 100 is given for each part and qualitative questions allow to better understand this global score month 6 for Intervention groupe and month 9 for control group
Secondary Number, description, classification (serious/non-serious) of adverse effects 9 months
Secondary Outcomes 1 to 12 evaluated at 6 months and at 9 months. We repeat the measure of outcomes 1 to 12 at 6 and 9 months from the randomization to see the evolution of each of them 9 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05659862 - Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT03042728 - Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program N/A
Recruiting NCT06097091 - Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia N/A
Recruiting NCT04554784 - Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia N/A
Completed NCT03300635 - Metabolism, Muscle Function and Psychological Factors in Fibromyalgia N/A
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT03227952 - Sensory Stimulation in Fibromyalgia N/A
Completed NCT03166995 - Postural Exercises in Women With Fibromyalgia N/A
Recruiting NCT06237595 - Vagus Nerve Stimulation in Fibromyalgia N/A
Completed NCT01888640 - Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST) N/A
Completed NCT03641495 - Pain Education and Therapeutic Exercise for Fibromyalgia N/A
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Active, not recruiting NCT05128162 - Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia Phase 2
Completed NCT04674878 - Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia N/A
Active, not recruiting NCT04084795 - Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia N/A
Completed NCT03129906 - Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients N/A
Completed NCT05058911 - Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia N/A
Recruiting NCT04571853 - New Educational Tool for FM N/A
Recruiting NCT04571528 - Effectiveness of VIRTUAL FIBROWALK STUDY N/A

External Links